COMMUNIQUÉS West-GlobeNewswire

Aduro Biotech to Host a Program Update Call
11/12/2017
BERKELEY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the company will host a [...]
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
11/12/2017
NEWTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra- [...]
New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML
11/12/2017
- First Expansion Data and Updated Dose-Escalation Data Support NDA Submission for IDH1m R/R AML by Year End 2017 and Demonstrate Overall Efficacy and Safety Profile Consistent with Previously Reported Data - - In 125 R [...]
NAPA’s Jonathan Markley Named to Top Doctor’s list by New Jersey Monthly
11/12/2017
MELVILLE, N.Y., Dec. 11, 2017 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) announced today that one of its leading practitioners, Jonathan Markley, DO, was selected as a Top Doctor in the [...]
Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
11/12/2017
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS ) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks [...]
FDA Approves Sanofi's Admelog® (insulin lispro injection)
11/12/2017
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA Approves Sanofi's Admelog ® (insulin lispro injection) First FDA-approved follow-on mealtime insulin Admelog (insulin lispro injection) 100 Units/mL will be [...]
La FDA approuve l'insuline lispro injectable Admelog® de Sanofi
11/12/2017
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) La FDA approuve l'insuline lispro injectable Admelog ® de Sanofi Première insuline prandiale « follow-on » [1] approuvée par la FDA Admelog (insuline [...]
U.S. Army Dental Corps Veteran Honored by the American College of Prosthodontists
11/12/2017
Chicago, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Ronald D. Woody, DDS, FACP , was honored with the Major General Bill B. Lefler Federal Services Award at the Annual Awards & President’s Dinner during the American College [...]
RedHawk Completes EcoGen Share Transfer Agreement
11/12/2017
LAFAYETTE, La., Dec. 11, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that along with its wholly-owned subsidiary, RedHawk Pharma UK Limited (“RedHawk Pharma [...]
Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis
11/12/2017
Almirall and Athenex have entered into a strategic partnership to develop and commercialize KX2-391 in the United States and Europe KX2-391 is a first-in-class topical treatment currently in Phase III development that [...]
Ossur Hf : Transactions in relation to share buyback program
11/12/2017
Announcement from Össur hf. No. 86/2017 Reykjavík, 11 December 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
11/12/2017
Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data Results were [...]
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
11/12/2017
Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohort Data supports combination with MGA012 (anti-PD-1) to potentially enhance anti-leukemic [...]
Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD
11/12/2017
BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced [...]
Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly
11/12/2017
Copenhagen, 2017-12-11 16:29 CET (GLOBE NEWSWIRE) -- With reference to company announcement no. 35/2017 and no. 36/2017 regarding offering, pricing and completing of the offering of new shares in ALK-Abelló A/S, company [...]
Novo Nordisk A/S - Share repurchase programme
11/12/2017
Bagsværd, Denmark, 11 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
11/12/2017
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase [...]
Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting
11/12/2017
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting
11/12/2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

Pages